KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19. PMID 39903535 · JCI Insight · 2025-Feb-04 The trial is a randomized, double-blind, placebo-controlled study of IL-7 in critically ill COVID-19 patients. It is human, includes a drug intervention, and reports original results. However, it is not an oncology study; it focuses on infectious disease (COVID-19). The primary endpoint is lymphocyte recovery, and secondary clinical endpoints are safety, length of stay, infections, and mortality. There is no mention of Kaplan-Meier analysis, hazard ratios, or other time-to-event efficacy endpoints for survival or disease progression. Therefore, it does not meet the oncology or time-to-event criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer. PMID 39354670 · Jpn J Clin Oncol · 2025-Feb-04 The record is a protocol abstract for a phase III randomized trial with a drug intervention, but it does not report results and the primary endpoint is not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 40009381 · JAMA Netw Open · 2025-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Algorithm-Based Palliative Care in Patients With Cancer: A Cluster Randomized Clinical Trial. PMID 39982729 · JAMA Netw Open · 2025-Feb-03 Eligible for review as a human malignant-neoplasm randomized trial with original results, but excluded because it does not have a drug-containing intervention (intervention is algorithm-based palliative care process) and lacks a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of deep diaphragmatic breathing on fatigue in patients with metastatic gastrointestinal cancers: a randomized clinical trial. PMID 39899118 · Support Care Cancer · 2025-Feb-03 The study is a randomized oncology trial with human patients, but the intervention is a non-drug behavioral therapy (deep diaphragmatic breathing) and the primary endpoint is fatigue, not a time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. PMID 39778968 · J Nucl Med · 2025-Feb-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy. PMID 39527097 · Cancer Immunol Res · 2025-Feb-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R). PMID 39894522 · BMJ Open · 2025-Feb-02 This is a clinical trial protocol for a randomized controlled trial. While it meets criteria for oncology, human, randomized, time-to-event endpoints, and drug intervention, it is not a formal report of trial results. The trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, and the deterministic review flagged phase3_evidence_unclear. Therefore, it is excluded as a protocol-without-results and due to insufficient evidence for the required phase.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Effect of the Second Forward View on the Detection Rate of Sessile Serrated Lesions in the Proximal Colon: A Single-Center Prospective Randomized Controlled Study. PMID 39688959 · Clin Transl Gastroenterol · 2025-Feb-01 Study is a randomized trial in oncology (colorectal cancer screening) but does not meet eligibility criteria: it is not a Phase III drug trial and has no time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Automated patient selection and care coaches to increase advance care planning for patients with cancer. PMID 39348179 · J Natl Cancer Inst · 2025-Feb-01 The study is a cluster-randomized, stepped-wedge trial in oncology patients, but it is not a drug trial, does not report Phase III/IIIb or Phase II/III status, and its primary endpoint is a process measure (proportion of visits with prognosis documentation), not a time-to-event efficacy endpoint like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating the Impact of Post-Esophagectomy Exercise on 2- and 5-Yr Survival: Findings from the PERFECT Trial. PMID 39293388 · Med Sci Sports Exerc · 2025-Feb-01 The record reports an original randomized trial with time-to-event endpoints in oncology, but the intervention is exercise-based, not drug-containing. Additionally, the trial phase is not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial. PMID 39270828 · Int J Radiat Oncol Biol Phys · 2025-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. PMID 38899967 · Hepatology · 2025-Feb-01 This is a prospective biomarker cohort study comparing diagnostic performance of HES V2.0, GALAD, and ASAP scores for HCC detection. It is not a randomized controlled trial. The primary endpoints are diagnostic accuracy metrics (sensitivity/TPR, AUROC), not time-to-event efficacy outcomes (OS, PFS, DFS, etc.). No drug intervention is described; the study evaluates diagnostic scores.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2. PMID 39992021 · J Cachexia Sarcopenia Muscle · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis. PMID 39980062 · Clin Transl Sci · 2025-Feb The study is a Phase III randomized trial of imetelstat in oncology, but the reported endpoint is a cardiac safety biomarker (QTcF prolongation) for proarrhythmic risk assessment. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or hazard ratio analysis. Therefore, it is excluded from the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. PMID 39979665 · Nat Cancer · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC. PMID 39957151 · Future Oncol · 2025-Feb The publication is a clinical trial protocol for an ongoing phase III randomized study in oncology with a drug intervention. It describes the study design but does not present results or data, so time-to-event efficacy endpoints (e.g., OS, PFS) cannot be assessed from the abstract. It is excluded as a protocol without results.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction to "Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29-Month Follow-Up From a Randomized, Open-Label, Phase III Trial". PMID 39927664 · Cancer Med · 2025-Feb The record is for a published erratum to a Phase III trial abstract, but the abstract content is missing. While the title indicates a 29-month follow-up from a randomized, open-label, Phase III trial (CheckMate 648) in esophageal squamous cell carcinoma with a drug-containing intervention, the absence of the abstract prevents confirmation of a time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) and whether this is an original result report. The publication type is an erratum, which is not a primary research report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. PMID 39921387 · Genes Chromosomes Cancer · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. PMID 39908699 · ESMO Open · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma. PMID 39903071 · Radiology · 2025-Feb The record describes a randomized, controlled trial in human oncology (HCC) with a primary OS endpoint and Kaplan-Meier analysis. However, it compares two non-drug interventions (TACE-RFA vs. SR). TACE is a procedure, and the intervention is not a systemic or investigational drug as defined by the criteria. Therefore, it is excluded as a non-drug-only trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort. PMID 39897613 · JHEP Rep · 2025-Feb The study is an observational cohort analysis, not a randomized controlled trial. While it reports Phase III-like results with time-to-event endpoints and drug intervention, the non-randomized design and lack of explicit Phase III/IIIb or Phase II/III trial classification exclude it.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Coping, Emotional Processing, and Cancer-Related Symptoms in Breast Cancer Survivors: Cross-Sectional Secondary Analysis of the REPAT Study. PMID 39891317 · Psychooncology · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
SELective defunctioning Stoma Approach in low anterior resection for rectal cancer (SELSA): Protocol for a prospective study with a nested randomized clinical trial investigating stoma-free survival without major LARS following total mesorectal excision. PMID 39887540 · Colorectal Dis · 2025-Feb 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
It is Time to Address Fear of Cancer Recurrence in Family Caregivers: Feasibility and Acceptability of a Randomized Pilot Study of the Family Caregiver Version of the Fear of Recurrence Therapy (FC-FORT). PMID 39887474 · Psychooncology · 2025-Feb This is a pilot/feasibility study of a psychosocial intervention (therapy) for family caregivers of cancer patients. It is not a Phase II/III or Phase III/IIIb randomized trial. It does not involve a drug intervention. The primary endpoints are feasibility and acceptability, not time-to-event efficacy endpoints like OS or PFS. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial. PMID 39874903 · ESMO Open · 2025-Feb The record is a Phase IIIb oncology trial with drug intervention and time-to-event endpoints, but it is not randomized, which is a required criterion for the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels. PMID 39874440 · Expert Rev Anticancer Ther · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. PMID 39862880 · Lancet Neurol · 2025-Feb 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. PMID 39862879 · Lancet Neurol · 2025-Feb 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study. PMID 39855251 · Lancet Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Role of bilevel erector spinae with high thoracic block vs conventional unilevel block in analgesia and reduction of pain in axilla in breast cancer surgeries: a randomized controlled trial. PMID 39816904 · Pain Rep · 2025-Feb The study is an original randomized trial in breast cancer patients, but it evaluates anesthetic/analgesic nerve block techniques, not a systemic drug therapy for efficacy. It lacks a Phase III classification and does not report time-to-event efficacy endpoints like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. PMID 39812928 · Int J Clin Oncol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer? PMID 39799639 · Clin Oncol (R Coll Radiol) · 2025-Feb This is a radiotherapy quality assurance report for the SCOPE2 trial, not a primary or secondary efficacy result report. It does not present drug intervention data or time-to-event outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study. PMID 39798422 · ESMO Open · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial. PMID 39755915 · CNS Drugs · 2025-Feb This is a randomized, open-label trial of evolocumab plus atorvastatin vs. atorvastatin alone for the prevention of early neurological deterioration in acute ischemic stroke. It is not an oncology (malignant neoplasm) study. The primary endpoint (early neurological deterioration within 7 days) is a categorical outcome (incidence), not a time-to-event endpoint (e.g., OS, PFS, DFS) analyzed with Kaplan-Meier or hazard ratios. The 90-day modified Rankin Scale score is also categorical. Therefore, it fails the core oncology and time-to-event criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. PMID 39753967 · Nat Med · 2025-Feb The record is a methodological study that uses machine learning to emulate and compare results from multiple existing RCTs. It is not an original report of a single randomized trial's results. Therefore, it does not meet the criterion of being an 'original formal-result report' of a single human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. PMID 39743436 · Arch Cardiovasc Dis · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. PMID 39739195 · Adv Ther · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
COLOR IV: a multicenter randomized clinical trial comparing intracorporeal and extracorporeal ileocolic anastomosis after laparoscopic right colectomy for colon cancer. PMID 39733171 · Surg Endosc · 2025-Feb 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis. PMID 39724774 · Eur J Obstet Gynecol Reprod Biol · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol. PMID 39706331 · Contemp Clin Trials · 2025-Feb 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China. PMID 39686857 · J Comp Eff Res · 2025-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial. PMID 39675479 · J Nutr · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Is the benefit of sequential 5-fluorouracil and daylight photodynamic therapy versus daylight photodynamic therapy alone sustained over time? - 12-month follow-up of a randomized controlled trial. PMID 39674293 · Photodiagnosis Photodyn Ther · 2025-Feb 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials. PMID 39636343 · Rheumatol Ther · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study. PMID 39630848 · Mol Oncol · 2025-Feb The record is an eligible oncology RCT with drug intervention and time-to-event endpoints, but it is a pre-specified translational/biomarker analysis of a subgroup within a larger trial, not the primary formal result report of the overall Phase III trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial. PMID 39562215 · Dig Liver Dis · 2025-Feb 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trial. PMID 39549836 · J Thromb Haemost · 2025-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer. PMID 39543869 · Clin Pharmacol Ther · 2025-Feb The record describes an exposure-response analysis combining data from phase I/II and phase III studies. While it contains results for PFS and OS from the phase III ASCENT trial, it is not the original primary or formal result report of that randomized trial. The analysis is a secondary pharmacometric study. Therefore, it does not meet the criterion of being an 'original formal-result report' of a single randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. PMID 39542422 · Ann Oncol · 2025-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -